Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangamo and Genentech expand agreement for protein production
ZFNs are engineered forms of zinc finger DNA-binding proteins that also contain a nuclease component, which can induce modification of a target gene of interest Edward Lanphier, president
ZFNs are engineered forms of zinc finger DNA-binding proteins that also contain a nuclease component, which can induce modification of a target gene of interest Edward Lanphier, president
The offering is expected to close on February 29, 2008. In connection with the offering, the company has also agreed to issue warrants to purchase an additional one
US health-care spending which was $2.2 trillion in 2007 is predicted to grow annually by about 6.7% for the next decade. GDP by contrast is expected to rise
The environment commissioner Stavros Dimas said that the main objective was to reduce the need for animal tests and promote alternative methods. The commission also maintained that it
The study showed that in comparison to placebo effects, antidepressants do not have clinically significant effects in mildly depressed patients or in most patients who suffer from very
Under the terms of the agreement, Shasun grants Merck the use of its proprietary cross-coupling copper technology (also known as Buchwald technology) to manufacture and commercialize APIs (active
Tentative FDA approval indicates that the FDA has concluded that Covidien’s generic product is safe and effective for use as recommended in the submitted labeling. Final approval of
As a result of this closing, Manhattan has received a $2 million cash payment plus $2.5 million of equity in the newly established joint venture, which has been
Under a collaborative research and exclusive license agreement, Receptor Logic will create custom TCRm in support of Sanofi Pasteur’s vaccine programs. Receptor Logic is funded and managed by
Under this CTA, Guiseppe Giaccone, chief of the medical oncology branch at NCI and his colleague, Martin Gutierrez, will conduct a Phase I clinical trial with Serenex’s novel,